Pathology, proteomics and the pathway to personalised medicine

Ping Jin, Jiang Lan, Kui Wang, Mark S Baker, Canhua Huang, Edouard C. Nice

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.

Original languageEnglish
Pages (from-to)231-243
Number of pages13
JournalExpert Review of Proteomics
Volume15
Issue number3
DOIs
Publication statusPublished - 4 Mar 2018

Keywords

  • big data
  • Biobanking
  • liquid biopsy
  • mass spectrometry
  • microarrays
  • pathology
  • personalized medicine
  • proteomics

Cite this

Jin, Ping ; Lan, Jiang ; Wang, Kui ; Baker, Mark S ; Huang, Canhua ; Nice, Edouard C. / Pathology, proteomics and the pathway to personalised medicine. In: Expert Review of Proteomics. 2018 ; Vol. 15, No. 3. pp. 231-243.
@article{1101319c8fd14de8abe4018d742ba4f5,
title = "Pathology, proteomics and the pathway to personalised medicine",
abstract = "Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.",
keywords = "big data, Biobanking, liquid biopsy, mass spectrometry, microarrays, pathology, personalized medicine, proteomics",
author = "Ping Jin and Jiang Lan and Kui Wang and Baker, {Mark S} and Canhua Huang and Nice, {Edouard C.}",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/14789450.2018.1425618",
language = "English",
volume = "15",
pages = "231--243",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor & Francis",
number = "3",

}

Pathology, proteomics and the pathway to personalised medicine. / Jin, Ping; Lan, Jiang; Wang, Kui; Baker, Mark S; Huang, Canhua; Nice, Edouard C.

In: Expert Review of Proteomics, Vol. 15, No. 3, 04.03.2018, p. 231-243.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Pathology, proteomics and the pathway to personalised medicine

AU - Jin, Ping

AU - Lan, Jiang

AU - Wang, Kui

AU - Baker, Mark S

AU - Huang, Canhua

AU - Nice, Edouard C.

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.

AB - Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.

KW - big data

KW - Biobanking

KW - liquid biopsy

KW - mass spectrometry

KW - microarrays

KW - pathology

KW - personalized medicine

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85041482491&partnerID=8YFLogxK

U2 - 10.1080/14789450.2018.1425618

DO - 10.1080/14789450.2018.1425618

M3 - Review Article

VL - 15

SP - 231

EP - 243

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 3

ER -